IBA receives down payment for Proteus®PLUS contract in Shenzhen, China
01 Octobre 2019 - 7:00AM
IBA receives down payment for Proteus®PLUS contract in Shenzhen,
China
Seven proton therapy rooms already sold by IBA
this year
Louvain-la-Neuve, Belgium, 1 October,
2019 - IBA (Ion Beam Applications
SA), the world’s leading provider of
proton therapy solutions for the treatment of cancer, announces
that it has received the down payment for the contract with the
Shenzhen Municipal People's Government to install a Proteus®PLUS*
proton therapy system in Shenzhen, China. As announced in the half
year financial update, IBA has already started to recognize revenue
for this contract, in line with the applicable accounting standard.
This contract, worth approximately EUR 90 million to IBA, brings
the total number of proton therapy rooms sold by IBA this year to
seven.
As previously announced, the proton therapy
center will be installed at the Shenzhen Tumor Hospital, which is a
member of the Chinese Academy of Medical Sciences (CAMS), and
treatment is expected to start on patients in 2022. CAMS is a
leading health network for cancer prevention and treatment in
China, which is active in cancer research, comprehensive education
and research-based prevention. This center will be the fifth IBA
Proteus®PLUS proton therapy solution in China.
IBA signed the contract following a
comprehensive public tender conducted by the Shenzhen Municipal
Health Commission. The selection of IBA highlights the Company’s
continued successful investment in this strategically important
region, the superiority of its proton therapy solutions and its
technological leadership, particularly with new developments such
as Organ Motion Management, and on-going research projects on Arc
Therapy and Flash irradiation. These novel techniques have the
potential to change the landscape of radiotherapy and patient
cancer care in the coming years.
-ENDS-
About IBAIBA (Ion Beam
Applications S.A.) is a global medical technology company focused
on bringing integrated and innovative solutions for the diagnosis
and treatment of cancer. The company is the worldwide technology
leader in the field of proton therapy, considered to be the most
advanced form of radiation therapy available today. IBA’s proton
therapy solutions are flexible and adaptable, allowing customers to
choose from universal full-scale proton therapy centers as well as
compact, single room solutions. In addition, IBA also has a
radiation dosimetry business and develops particle accelerators for
the medical world and industry. Headquartered in Belgium and
employing about 1,400 people worldwide, IBA has installed systems
across the world.
IBA is listed on the pan-European stock exchange
NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at: www.iba-worldwide.com
* Proteus®PLUS is the brand name of
Proteus®235
For further information, please
contact:
IBA
Soumya
ChandramouliChief Financial Officer+32 10
475 890Investorrelations@iba-group.com
Thomas RaletVice-President
Corporate Communication+32 10 475
890communication@iba-group.com
For media and investor
enquiries:
Consilium Strategic
CommunicationsAmber Fennell, Angela Gray, Lizzie Seeley+44
(0) 20 3709 5700IBA@consilium-comms.com
-
19.10.01-IBA_receives_down_payment_for_ProteusPLUS_contract_in_Shenzhen_China
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024